首页 > 市场调查报告书 > 製药

呼吸器

肺药市场：按药物类别、应用、分销渠道、地区 - 规模、份额、前景、机会分析，2022-2030

市场调查报告书

商品编码

1110119

肺药市场：按药物类别、应用、分销渠道、地区 - 规模、份额、前景、机会分析，2022-2030

Pulmonary Drugs Market, by Drug Class, by Application, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年07月14日 | 出版商:

Coherent Market Insights | 英文 304 Pages | 商品交期: 2-3个工作天内

价格

简介目录

肺药用于治疗影响肺部的疾病。肺部药物用于治疗普通感冒等轻度疾病到哮喘等长期疾病。这些药物有多种形式，包括口服片剂、口服液、注射剂和吸入器。吸入器将药物直接输送到肺部，在那里它直接作用于肺组织，从而最大限度地减少全身副作用。

市场动态

推动肺药市场增长的主要因素包括慢性呼吸道疾病发病率的增加、吸烟、政府和非政府举措。根据疾病控制和预防中心 (CDC) 的数据，2015 年美国有 2500 万人患有哮喘病，这相当于每 13 个美国人中就有 1 个患有哮喘病。 620 万 18 岁以下的人患有哮喘。哮喘每年造成 1420 万次就诊和 180 万次救护车就诊。此外，大量品牌药物的专利到期、研发资金以及创新产品的推出预计将成为预测期内市场增长的主要因素。例如，在 2017 年，葛兰素史克获得了美国 FDA 对一种名为 Trelegy Ellipta 的专有三合一吸入器的批准，用于治疗慢性肺病。 Trelegy Ellipta 将三种治疗方法结合到一个吸入器中，从而为患者提供新的治疗选择。然而，大量未确诊的患者以及与服用这些导致肾臟问题导致不良事件的药物相关的副作用预计将限制市场的增长。

本研究的主要特点

本报告对肺药市场进行了深入分析，提供了以 2017 年为基准年的预测期（2017-2025 年）的市场规模和累计年增长率 (CAGR %)。
说明不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
该研究还提供了有关市场驱动因素、限制因素、机遇、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
根据以下参数来描述全球肺部药物市场的主要参与者 - 公司概况、财务业绩、产品组合、市场存在、分销战略、关键发展、战略和未来计划
本研究涵盖的主要公司包括 Sanofi SA、Meda Pharmaceuticals、Circassia Pharmaceuticals Plc.、AstraZeneca Plc.、GlaxoSmithKline Plc.、Mallinckrodt Pharmaceuticals Plc.、Cheisi Farmaceuticals S.p.A、Zambon Company S.p.A、Alaxia SAS 和 Merck Sharp & Dohme 有限公司
本报告中的见解将使营销人员和企业高管能够就未来的产品发布、技术升级、市场扩张和营销策略做出明智的决策。
全球肺治疗市场报告迎合了该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和财务分析师。
将通过用于分析肺治疗市场的各种战略矩阵，为利益相关方制定决策提供便利。

内容

第 1 章目的和先决条件

调查目的
先决条件
缩写说明

第2章市场展望

举报内容
- 市场定义和范围
执行摘要
- 市场快照：按药物类别
- 市场快照：按应用
- 市场快照：按分销渠道
- 市场概况：按地区划分
连贯的机会图 (COM)

第 3 章市场动态、监管和趋势分析

市场动态
- 驱动程序
- 限制因素
- 市场机会
监管场景
管道分析
促销活动和活动
供应链分析
PEST 分析
流行病学

第 4 章全球肺药市场 - 冠状病毒 (COVID-19) 大流行的影响

整体影响
政府举措
COVID-19 对市场的影响

第 5 章。2017-2030 年按药物类别分列的全球肺药市场

吸入性皮质类固醇
长效β2激动剂
抗组胺药
血管扩张剂
短效 β-2 激动剂
其他

第 6 章。2017-2030 年按应用分列的全球肺药市场

支气管哮喘和慢性阻塞性肺病
过敏性鼻炎
肺动脉高压
囊性纤维化
其他

第 7 章。2017-2030 年全球肺药市场，按分销渠道分列

医院药房
零售药房
电子商务

第 8 章。全球肺药市场：按地区划分，2017-2030 年

北美
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地区
欧洲
英国
德国
意大利
法国
西班牙
俄罗斯
其他欧洲
亚太地区
中国
印度
日本
东盟
澳大利亚
韩国
其他亚太地区
中东
海合会
以色列
其他中东地区
非洲
北非
中非
南非

第 9 章竞争格局

热图分析
市场份额分析（3x3 矩阵）
公司简介
- Sanofi SA
- Meda Pharmaceuticals
- Circassia Pharmaceuticals Plc.
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Mallinckrodt Pharmaceuticals Plc.
- Cheisi Farmaceutici S.p.A
- Zambon Company S.p.A
- Alaxia SAS
- Merck Sharp & Dohme Limited

第10章章节

参考文献
调查手法介绍

简介目录

Product Code: CMI1285

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

Market Dynamics

The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.

Key features of the study:

This report provides in-depth analysis of pulmonary drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 - 2025), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global pulmonary drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market

Detailed Segmentation:

Global Pulmonary Drugs Market, By Drug Class:
- Inhaled Corticosteroids
- Long Acting Beta-2 Agonists
- Antihistamines
- Vasodilators
- Short Acting Beta-2 Agonists
- Others
Global Pulmonary Drugs Market, By Application:
- Asthma & COPD
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
- Others
Global Pulmonary Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
Global Pulmonary Drugs Market, By Geography:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Sanofi SA*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments
- Meda Pharmaceuticals
- Circassia Pharmaceuticals Plc.
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Mallinckrodt Pharmaceuticals Plc.
- Cheisi Farmaceutici S.p.A
- Zambon Company S.p.A
- Alaxia SAS
- Merck Sharp & Dohme Limited

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
Pipeline Analysis
Promotional Activities and Campaigns
Supply Chain Analysis
PEST Analysis
Epidemiology

4. Global Pulmonary Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Pulmonary Drugs Market, By Drug Class, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Inhaled Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Long Acting Beta-2 Agonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Antihistamines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Vasodilators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Short Acting Beta-2 Agonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

6. Global Pulmonary Drugs Market, By Application , 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Asthma & COPD
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Allergic Rhinitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Pulmonary Arterial Hypertension
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Cystic Fibrosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

7. Global Pulmonary Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
E-Commerce
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

8. Global Pulmonary Drugs Market, By Region, 2017 - 2030, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
UK
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
North Africa
Central Africa
South Africa